Latest News and Press Releases

BRIDGEWATER, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced an offering of 12,281,000 shares of its common stock in a registered...

BRIDGEWATER, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $250 million of shares of its common...

Study met primary endpoint of culture conversion (p< 0.0001)Positive top-line results from global Phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection...

On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month  Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis...

BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...

BRIDGEWATER, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today...

BRIDGEWATER, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today...

BRIDGEWATER, N.J., June 08, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...

-- Paolo Tombesi named as Chief Financial Officer ---- Paul Streck, M.D., appointed as Chief Medical Officer ---- Eugene Sullivan, M.D., assumes role of Chief Product Strategy Officer --BRIDGEWATER,...

Advancing Toward Top-Line Results from CONVERT Study in 2H 2017 Conference call today at 8:30 AM ET BRIDGEWATER, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM),...